Actively Recruiting

Age: 5Years - 80Years
All Genders
ID02964364

China Takayasu Arteritis Registry (CTA Registry)

Led by Aimin Dang · Updated on 2016-11-16

1000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Takayasu arteritis (TA) is a rare chronic inflammation affecting the aorta and its main branches, mostly occurring in China. Researchers aim to better understand the disease's characteristics, diagnosis, activity, severity, treatment, and outcomes in Chinese patients by building a national registry. Previous studies identified certain gene alleles linked to TA and found cytokines like hs-CRP, NT-proBNP, and tumor necrosis factor-alpha useful for monitoring disease activity, but more research is needed to clarify its causes and effects. This observational study collects real-world information from Chinese TA patients to analyze disease features and support the development of effective monitoring and treatment strategies. There are no specific treatments or interventions assigned; instead, data regarding patients' conditions and outcomes are recorded over time to gain insights. Participants will be followed for up to 10 years, during which the researchers will track mortality and major cardiac and cerebrovascular events. The study gathers detailed clinical data, including disease activity markers and treatment responses, to understand patient outcomes better. The long-term follow-up aims to improve knowledge for managing TA and improving patient care.

CONDITIONS

Brief Title

China Takayasu Arteritis Registry (CTA Registry)

Who Can Participate

Age: 5Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age at disease onset less than 40 years
  • Development of symptoms or findings related to Takayasu arteritis before age 40
  • Claudication of extremities, meaning fatigue and discomfort in muscles of one or more limbs during use
  • Decreased pulse in one or both brachial arteries
  • Difference greater than 10 mm Hg in systolic blood pressure between arms
  • Audible bruit on auscultation over one or both subclavian arteries or abdominal aorta
  • Abnormal arteriogram showing narrowing or blockage of the aorta, its main branches, or large arteries in limbs, excluding arteriosclerosis or similar causes
Not Eligible

You will not qualify if you...

  • Vessel lesions that could be entirely caused by atherosclerosis
  • Giant cell arteritis or other infectious forms of large vessel vasculitis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Long-term Monitoring

Duration - Up to 10 years

Participants who are registered in the Chinese national Takayasu arteritis registry are observed to collect real-world information on disease characteristics, diagnosis, activity, severity, treatment, and outcomes over time.

Periodic visits as part of routine clinical follow-up

Trial Site Locations

Total: 1 location

1

Fuwai Hospital

Beijing, Beijing Municipality, China, 100037

Actively Recruiting

Loading map...

Research Team

A

Aimin Dang, MD,PhD

N

Naqiang lv, MD,PhD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

A Pilot Study in the Treatment of Severe Patients With Takay...

Takayasu Arteritis

Actively Recruiting

1 location

A Randomized, Controlled, Open-label, Multicenter Trial Comp...

Takayasu Arteritis

Actively Recruiting

1 location

Armenian Nationwide Registry of Systemic Autoimmune and Auto...

Behcet Disease

Actively Recruiting

6 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here